149 related articles for article (PubMed ID: 36306447)
1.
Rani S; Sahoo RK; Kumar V; Chaurasiya A; Kulkarni O; Mahale A; Katke S; Kuche K; Yadav V; Jain S; Nakhate KT; Ajazuddin ; Gupta U
Mol Pharm; 2023 Jan; 20(1):524-544. PubMed ID: 36306447
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
3. Biotinylated HPMA centered polymeric nanoparticles for Bortezomib delivery.
Rani S; Sahoo RK; Nakhate KT; Ajazuddin ; Gupta U
Int J Pharm; 2020 Apr; 579():119173. PubMed ID: 32097684
[TBL] [Abstract][Full Text] [Related]
4. Sialic Acid Engineered Prodrug Nanoparticles for Codelivery of Bortezomib and Selenium in Tumor Bearing Mice.
Rani S; Sahoo RK; Mahale A; Panchal K; Chaurasiya A; Kulkarni O; Kuche K; Jain S; Nakhate KT; Ajazuddin ; Gupta U
Bioconjug Chem; 2023 Sep; 34(9):1528-1552. PubMed ID: 37603704
[TBL] [Abstract][Full Text] [Related]
5. Glycine-Poly-L-Lactic Acid Copolymeric Nanoparticles for the Efficient Delivery of Bortezomib.
Rajoria S; Rani S; Chaudhari D; Jain S; Gupta U
Pharm Res; 2019 Sep; 36(11):160. PubMed ID: 31520196
[TBL] [Abstract][Full Text] [Related]
6. Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
Yin YP; Shi WH; Deng K; Liu XL; Li H; Lv XT; Lui VWY; Ding C; Hong B; Lin WC
Acta Pharmacol Sin; 2021 Aug; 42(8):1298-1310. PubMed ID: 33139838
[TBL] [Abstract][Full Text] [Related]
7. Dual pH-Responsive Shell-Cleavable Polycarbonate Micellar Nanoparticles for in Vivo Anticancer Drug Delivery.
Liu S; Ono RJ; Yang C; Gao S; Ming Tan JY; Hedrick JL; Yang YY
ACS Appl Mater Interfaces; 2018 Jun; 10(23):19355-19364. PubMed ID: 29757607
[TBL] [Abstract][Full Text] [Related]
8. Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer.
Xiao K; Li YP; Wang C; Ahmad S; Vu M; Kuma K; Cheng YQ; Lam KS
Biomaterials; 2015 Oct; 67():183-93. PubMed ID: 26218744
[TBL] [Abstract][Full Text] [Related]
9. Catechol polymers for pH-responsive, targeted drug delivery to cancer cells.
Su J; Chen F; Cryns VL; Messersmith PB
J Am Chem Soc; 2011 Aug; 133(31):11850-3. PubMed ID: 21751810
[TBL] [Abstract][Full Text] [Related]
10. Multifunctional Telodendrimer Nanocarriers Restore Synergy of Bortezomib and Doxorubicin in Ovarian Cancer Treatment.
Wang L; Shi C; Wright FA; Guo D; Wang X; Wang D; Wojcikiewicz RJH; Luo J
Cancer Res; 2017 Jun; 77(12):3293-3305. PubMed ID: 28396359
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
[TBL] [Abstract][Full Text] [Related]
12. Use of pH-Active Catechol-Bearing Polymeric Nanogels with Glutathione-Responsive Dissociation to Codeliver Bortezomib and Doxorubicin for the Synergistic Therapy of Cancer.
Qiu Y; Bai J; Feng Y; Shi X; Zhao X
ACS Appl Mater Interfaces; 2021 Aug; 13(31):36926-36937. PubMed ID: 34319074
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib-loaded mixed micelles realize a "three-in-one" effect for enhanced breast cancer treatment.
Liu J; Xu X; Li Y; Xu J; Zhao R; Liu S; Wu J; Zhang L; Zhang B
Biomater Sci; 2023 Jul; 11(14):4890-4906. PubMed ID: 37306225
[TBL] [Abstract][Full Text] [Related]
14. Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations.
Liu J; Zhao R; Jiang X; Li Z; Zhang B
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053199
[TBL] [Abstract][Full Text] [Related]
15. The γ-secretase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis.
Dang Q; Chen L; Xu M; You X; Zhou H; Zhang Y; Shi W
Cell Signal; 2019 Jul; 59():76-84. PubMed ID: 30878517
[TBL] [Abstract][Full Text] [Related]
16. PEGylated Dendrimer Mediated Delivery of Bortezomib: Drug Conjugation versus Encapsulation.
Sahoo RK; Gothwal A; Rani S; Nakhate KT; Ajazuddin ; Gupta U
Int J Pharm; 2020 Jun; 584():119389. PubMed ID: 32380027
[TBL] [Abstract][Full Text] [Related]
17. Resistance to bortezomib in breast cancer cells that downregulate Bim through FOXA1 O-GlcNAcylation.
Liu Y; Wang X; Zhu T; Zhang N; Wang L; Huang T; Cao Y; Li W; Zhang J
J Cell Physiol; 2019 Aug; 234(10):17527-17537. PubMed ID: 30793308
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy.
Zhu J; Huo Q; Xu M; Yang F; Li Y; Shi H; Niu Y; Liu Y
Nanoscale; 2018 Oct; 10(38):18387-18397. PubMed ID: 30256367
[TBL] [Abstract][Full Text] [Related]
19. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
Hideshima T; Qi J; Paranal RM; Tang W; Greenberg E; West N; Colling ME; Estiu G; Mazitschek R; Perry JA; Ohguchi H; Cottini F; Mimura N; Görgün G; Tai YT; Richardson PG; Carrasco RD; Wiest O; Schreiber SL; Anderson KC; Bradner JE
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13162-13167. PubMed ID: 27799547
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
